Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Philippe Mabo
During this session, dedicated to atrial fibrillation (AF), two debates were scheduled. The first one was dedicated to AF ablation in long term persistent AF, and the second one to potential indications of left atrial appendage (LLA) closure device.
Catheter ablation is indicated in long-term persistent atrial fibrillation: Pro, presented by C de Chillou (Vandoeuvre Les Nancy, FR) - Slides, Rebuttal Slides
Catheter ablation is indicated in long-term persistent atrial fibrillation: Contra, presented by A J Camm (London, GB) - Slides, Rebuttal Slides
Antithrombotic therapy will eliminate the need for closure devices: Pro, presented by E Hylek (Boston, US) - Slides, Rebuttal Slides
Antithrombotic therapy will eliminate the need for closure devices: Contra, presented by B Schumacher (Bad Neustadt A. D. Saale, DE) - Slides, Rebuttal Slides
Prof. de Chilloux (Nancy – France) was the speaker “pro”, defending the role of ablation in long lasting persistent AF. His talk was essentially based on the need for treatment, as patients are clinically invalidated by AF, and on the lack of efficacy of drug treatment. He also discussed the results of AF ablation in these specific patients and the acceptable rate of success in the absence of alternatives when drugs have failed. He pointed out the predictive value of sinus rhythm on survival of the patients successively treated, comparable to the rate of patients without history of AF and, on the contrary, the bad prognosis of permanent AF patients. Prof. Camm (London, GB), “contra”, highlighted the total absence of proof of the overall benefit of AF ablation in long lasting persistent AF without data on long term follow up, the low success rate and the risk of complications related to complex procedures. During the second debate, E. Hylek (Boston, USA) demonstrated the absence of need for LLA occluder. According to her, these devices are only indicated in patients with a contra-indication of oral anticoagulation treatment, and these patients do not really exist if we consider the overall risk/benefit ratio of this therapy, especially after the presentation of the ARISTOTLE trial. LAA occluder implant is associated with acute complication and Dr. Hylek highlighted the weakness of the data on LLA occluder clinical validation. Dr. Schumacher (Bad Neustad – DE) has shown the results of the Protect trial and concluded to acceptable results in terms of feasibility, of acute adverse events and mid-term clinical benefit.
As a comment of this session, we may conclude that both interventional procedures need to be more deeply clinically evaluated to really demonstrate a positive benefit/risk ratio. Even if we may expect large improvement in AF ablation techniques, the results observed with the new OAC drugs may constitute a new obstacle for the development of LLA occluders.
Controversial issues in atrial fibrillation management
© 2017 European Society of Cardiology. All rights reserved